All‐cause mortality · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes all‐cause mortality compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Cardiovascular events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes cardiovascular events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Total serious adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes total serious adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Heart failure hospitalisation (RR) · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes hospitalisation for heart failure compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (18 years of age or older) with hypertension‐induced left ventricular hypertrophy
It is very uncertain whether antihypertensive therapy changes withdrawal due to adverse events compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower total cardiovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower cerebrovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in coronary heart disease mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Decrease in SBP5 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Decrease in DBP6 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Sudden cardiac death · patients with hypertension
Antihypertensive pharmacotherapy showed no clear difference in sudden cardiac death ( compared with control (moderate certainty).
1 finding from 1 review
Non‐fatal MI · patients with hypertension
Antihypertensive pharmacotherapy probably leads to lower non‐fatal myocardial infarction ( compared with control (moderate certainty).
1 finding from 1 review
Fatal myocardial infarction ( · patients with hypertension
Antihypertensive pharmacotherapy probably leads to lower fatal myocardial infarction ( compared with control (moderate certainty).
1 finding from 1 review